Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.
Tomefa E AsempaAbigail K KoisChristian M GillYasmeen AbouelhassanPublished in: The Journal of antimicrobial chemotherapy (2023)
Data demonstrate that current imipenem/relebactam and ceftazidime/avibactam CLSI breakpoints are appropriate. Data also suggest that higher meropenem/vaborbactam breakpoints relative to meropenem can translate to potentially poor clinical outcomes in patients infected with OXA-48-harbouring isolates.
Keyphrases
- gram negative
- klebsiella pneumoniae
- multidrug resistant
- acinetobacter baumannii
- end stage renal disease
- electronic health record
- ejection fraction
- newly diagnosed
- chronic kidney disease
- escherichia coli
- big data
- prognostic factors
- peritoneal dialysis
- drug resistant
- machine learning
- patient reported outcomes
- pseudomonas aeruginosa